Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
Clinical trial NCT05510427 · WITHDRAWN
Trial details
- NCT number
- NCT05510427
- Sponsor
- M.D. Anderson Cancer Center
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-07
- Primary completion
- 2023-08-07
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.